nach oben

Cardiovascular Toxicology

Erschienen in:

01.09.2010

Comparison of the Effects of Methadone and Heroin on Human ether-à-go-go-Related Gene Channels

verfasst von: Bernd J. Zünkler, Maria Wos-Maganga

Erschienen in: Cardiovascular Toxicology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Torsades de pointes (TdP) is a life-threatening form of ventricular arrhythmia that occurs under conditions of delayed cardiac repolarization indicated by prolonged QT intervals in ECG recordings. The main mechanism of QT prolongation and TdP is block of the rapid component of the cardiac delayed rectifier K⁺ current (I_Kr), which is encoded by hERG (human ether-à-go-go-related gene). The opioid agonist methadone has previously been demonstrated to inhibit hERG currents, and there are reports of serious cardiac arrhythmias and deaths from TdP and ventricular fibrillation in patients taking methadone. The aim of the present study was to compare the effects of the opioid agonists methadone and heroin (3,6-diacetylmorphine) on hERG currents stably expressed in human embryonic kidney (HEK 293) cells using the whole-cell configuration of the patch-clamp technique. Both methadone and heroin inhibit hERG currents in a concentration-dependent manner. The following values were calculated for IC₅₀ (concentration causing half-maximal inhibition) and n (the Hill coefficient): 4.8 μM and 0.9 for methadone, 427 μM and 0.7 for heroin. In conclusion, the potency for block of hERG currents is about 100-fold lower for heroin when compared to methadone.

Keating, M. T., & Sanguinetti, M. C. (1996). Molecular genetic insights into cardiovascular disease. Science, 272, 681–685.CrossRefPubMed

Warmke, J. W., & Ganetzky, B. (1994). A family of potassium channel genes related to eag in Drosophila and mammals. Proceedings of the National Academy of Sciences of the United States of America, 91, 3438–3442.CrossRefPubMed

Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia. Cell, 81, 299–307.CrossRefPubMed

Trudeau, M. C., Warmke, J. W., Ganetzky, B., & Robertson, G. A. (1995). hERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269, 92–95.CrossRefPubMed

Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., & De Ponti, F. (2005). QT prolongation through hERG K⁺ channel blockade: Current knowledge and strategies for the early prediction during drug development. Medicinal Research Reviews, 25, 133–166.CrossRefPubMed

Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.CrossRefPubMed

International conference on harmonization S7B guideline (CPMP/ICH/423/02; 2005). The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. http://www.emea.europa.eu/pdfs/human/ich/042302en.pdf.

Katchman, A. N., McGroary, K. A., Kilborn, M. J., Kornick, C. A., Manfredi, P. L., Woosley, R. L., et al. (2002). Influence of opioid agonists on cardiac human ether-a-go-go-related gene K⁺ currents. Journal of Pharmacology and Experimental Therapeutics, 303, 688–694.CrossRefPubMed

Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Deglon, J.-J., et al. (2007). Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical Pharmacology and Therapeutics, 81, 719–728.CrossRefPubMed

10.

Krantz, M. J., Martin, J., Stimmel, B., Mehta, D., & Haigney, M. C. P. (2009). QTc interval screening in methadone treatment. Annals of Internal Medicine, 150, 387–395.PubMed

11.

Lin, C., Somberg, T., Molnar, J., & Somberg, J. (2009). The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology, 113, 59–65.CrossRefPubMed

12.

Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981). Improved patch-clamp techniques for high-resolution current recordings from cells and cell-free membrane patches. Pfluegers Archiv, 391, 85–100.CrossRefPubMed

13.

de Vos, J. W., Geerlings, P. J., van den Brink, W., Ufkes, J. G., & van Wilgenburg, H. (1995). Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. European Journal of Clinical Pharmacology, 48, 361–366.CrossRefPubMed

14.

Romach, M. K., Piafsky, K. M., Abel, J. G., Khouw, V., & Sellers, E. M. (1981). Methadone binding to orosomucoid (alpha 1-acid glycoprotein): Determinant of free fraction in plasma. Clinical Pharmacology and Therapeutics, 29, 211–217.CrossRefPubMed

15.

Inturrisi, C. E., Colburn, W. A., Kaiko, R. F., Houde, R. W., & Foley, K. M. (1987). Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clinical Pharmacology and Therapeutics, 41, 392–401.CrossRefPubMed

16.

Benmebarek, M., Devaud, C., Gex-Fabry, M., Powell Golay, K., Brogli, C., Baumann, P., et al. (2004). Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clinical Pharmacology and Therapeutics, 76, 55–63.CrossRefPubMed

17.

Rook, E. J., Huitema, A. D. R., van den Brink, W., van Ree, J. M., & Beijnen, J. H. (2006). Population pharmacokinetics of heroin and its major metabolites. Clinical Pharmacokinetics, 45, 401–417.CrossRefPubMed

18.

Cohn, G. L., Cramer, J. A., McBride, W., Brown, R. C., & Kleber, H. D. (1974). Heroin and morphine binding with human serum proteins and red blood cells. Proceedings of the Society for Experimental Biology and Medicine, 147, 664–666.PubMed

19.

Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., & Sanguinetti, M. C. (2000). A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America, 97, 12329–12333.CrossRefPubMed

20.

Sanguinetti, M. C., & Mitcheson, J. S. (2005). Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends in Pharmacological Sciences, 26, 119–124.CrossRefPubMed

21.

Zünkler, B. J. (2006). Human ether-a-go-go-related (hERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacology and Therapeutics, 112, 12–37.CrossRefPubMed

22.

Milnes, J. T., Crociani, O., Arcangeli, A., Hancox, J. C., & Witchel, H. J. (2003). Blockade of hERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. British Journal of Pharmacology, 139, 887–898.CrossRefPubMed

23.

Mitcheson, J. S. (2003). Drug binding to hERG channels: Evidence for a “non-aromatic” binding site for fluvoxamine. British Journal of Pharmacology, 139, 883–884.CrossRefPubMed

24.

Stork, D., Timin, E. N., Berjukow, S., Huber, C., Hohaus, A., Auer, M., et al. (2007). State dependent dissociation of hERG channel inhibitors. British Journal of Pharmacology, 151, 1368–1376.CrossRefPubMed

Titel: Comparison of the Effects of Methadone and Heroin on Human ether-à-go-go-Related Gene Channels
verfasst von: Bernd J. Zünkler
Maria Wos-Maganga
Publikationsdatum: 01.09.2010
Verlag: Humana Press Inc
Erschienen in: Cardiovascular Toxicology / Ausgabe 3/2010
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-010-9074-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Arsenic Induces Apoptosis of Human Umbilical Vein Endothelial Cells Through Mitochondrial Pathways

Purine Bases Oxidation and Repair Following Permethrin Insecticide Treatment in Rat Heart Cells

T Lymphocyte Regulation of Lysyl Oxidase in Diet-Induced Cardiac Fibrosis

Cytochrome c Oxidase is Essential for Copper-Induced Regression of Cardiomyocyte Hypertrophy

The Novel Role of Fenofibrate in Preventing Nicotine- and Sodium Arsenite-Induced Vascular Endothelial Dysfunction in the Rat

Protective Effects of Rutin on Mitochondrial Damage in Isoproterenol-Induced Cardiotoxic Rats: An In Vivo and In Vitro Study